Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder Cancer in a scientific article that was issue cover in an recognized international journal (Diagnostics). The details of this study can be found at: https://www.mdpi.com/2075-4418/10/1/39/htm
In times of covid19, cancer patients have a new way to avoid delaying diagnostic procedures and surveillance of bladder tumours.
Concerned about the postponement of surveillance procedures and the increased risk of contamination in Hospitals, a team of researchers from Ipatimup and the Institute for Research and Innovation in Health (i3S) validated a new form of bladder cancer surveillance that, from now on, may be carried-out from home. Bladder cancer mainly affects smoking men over… Read more »
Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study
The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer. The details of this… Read more »
Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment. The details of this study can be found… Read more »
Uromonitor as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer – article in uro today
Please read the full article here.
Uromonitor was highlighted on a portuguese paper. Non-invasive and low cost were two of the advantages mentioned on the article.
The president of the Everis Foundation, Eugenio Galdón, has awarded the Everis Prize 2015 to Hugo Prazeres for his Uromonitor project, a non-invasive test to detect bladder cancer by using a biomarker in urine samples, whose use avoids performing a cystoscopy, an uncomfortable procedure for the patient and expensive for the Public Health System. Read… Read more »
The test is currently performed as a service at Uromonitor, hosted at the above mentioned institutions.
To access the service, urologists in hospitals and clinics should first have materials for urine collection and shipment.
Direct ordering the complete analysis kit to be performed in a laboratory or medical unit.
Recommended for professionals!
“For persons at risk or patients diagnosed with bladder cancer, as well as their urologist, who have the need of more convenient surveillance methods, Uromonitor is a completely non-invasive, urine-based, In vitro Diagnosis (IVD) kit that is able to detect bladder cancer with high sensitivity and specificity.
Uromonitor is easy and can deliver reliable results to reduce costs with follow-up”.